Management of Lymphocytopenia with Neutrophilia

Patient Assessment and Risk Stratification

• High-risk patients, defined as those with a MASCC score <21, hemodynamic instability, significant comorbidities, prolonged neutropenia (>7 days), or profound neutropenia (ANC <100 cells/μL), require immediate broad-spectrum IV antibiotics and consideration of hospital admission 1, 2
• Low-risk patients, characterized by a MASCC score ≥21, stable vital signs, few comorbidities, and brief expected neutropenia (<7 days), may be considered for oral antibiotics if hemodynamically stable 1, 2
• The MASCC scoring index can be used to determine the risk level of patients, with scores ≥21 indicating low risk (6% serious complication rate, 1% mortality) and scores <21 indicating high risk, considering factors such as burden of illness, blood pressure, presence of COPD, solid tumor/lymphoma history, hydration status, outpatient status, and age 2
• Risk stratification should be performed based on the duration of abnormalities, including acute vs. chronic presentation and response to previous interventions 3, 4

Diagnostic Evaluation

• Flow cytometry is essential to confirm clonality and determine immunophenotype, and should be performed as part of the diagnostic workup 1, 5
• Serum protein electrophoresis to assess for hypogammaglobulinemia or paraproteinemia is also recommended 1, 5
• Bone marrow biopsy may be necessary for definitive diagnosis, as suggested by the American Society of Hematology 1
• The following table summarizes the criteria for defining leukocytosis and neutrophilia:

6, 7

• Neutrophilia has a high likelihood ratio (3.7) for detecting documented bacterial infection, even in the absence of fever 7
• Elevated total band count (>1,500/mm³) has the highest likelihood ratio (14.5) for bacterial infection 7

Treatment and Management

• Granulocyte colony-stimulating factor (G-CSF; filgrastim) at 5 μg/kg/day subcutaneously can be safely initiated to treat neutropenia, and should be continued until ANC is at least 500/mm³ 1
• Antibacterial prophylaxis with levofloxacin or ciprofloxacin 500 mg orally daily is recommended until ANC >500/mm³ 1
• For prolonged lymphocytopenia, pneumocystis prophylaxis (trimethoprim-sulfamethoxazole), antiviral prophylaxis (acyclovir or valacyclovir), and continuation of these for at least 3-6 months or until CD4 counts >200 cells/mm³ are recommended 1
• Daily assessment of fever trends and neutrophil counts until resolution is recommended, with consideration of changing to oral antibiotics if afebrile and ANC ≥0.5×10⁹/L at 48h 2, 8
• Discontinue antibiotics if neutrophil count is ≥0.5×10⁹/L, patient is asymptomatic, afebrile for 48h, and blood cultures are negative, as recommended by the Infectious Diseases Society of America and the European Society for Medical Oncology 2, 8

Avoiding Common Pitfalls

• Delaying empiric antibiotic therapy in suspected infection with neutrophilia is not recommended, as per the Centers for Disease Control and Prevention and the European Association for the Study of the Liver guidelines 8, 9, 10, 11
• Using aminoglycosides as empiric therapy is also not recommended due to the risk of nephrotoxicity, as stated by the National Institutes of Health and the Infectious Diseases Society of America 8, 2
• Failing to obtain appropriate cultures before initiating antimicrobial therapy is a common pitfall that should be avoided, as emphasized by the World Health Organization and the Infectious Diseases Society of America 8, 4
• Neglecting to evaluate for secondary bacterial peritonitis in patients with localized abdominal symptoms, multiple organisms on ascitic culture, very high ascitic neutrophil count, or inadequate response to therapy should be avoided, as warned by the European Association for the Study of the Liver 9
• Performing colonoscopy in neutropenic enterocolitis is contraindicated, as recommended by the European Society for Medical Oncology 12